A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
390 patients around the world
Available in Puerto Rico, United States, Brazil
AbbVie
2Research sites
390Patients around the world
This study is for people with
Colorectal cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Laboratory values meeting the criteria within the protocol.
Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
Sites
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
